Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Durect Corp (DRRX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 97,236
  • Shares Outstanding, K 162,060
  • Annual Sales, $ 49,170 K
  • Annual Income, $ -3,700 K
  • 36-Month Beta 1.49
  • Price/Sales 2.64
  • Price/Cash Flow N/A
  • Price/Book 3.89
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.06
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 03/07/19
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate -0.05
  • Number of Estimates 3
  • High Estimate -0.05
  • Low Estimate -0.05
  • Prior Year 0.05
  • Growth Rate Est. (year over year) -200.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.46 +26.09%
on 12/28/18
0.69 -16.55%
on 01/16/19
-0.06 (-9.38%)
since 12/18/18
3-Month
0.46 +26.09%
on 12/28/18
1.10 -47.27%
on 10/31/18
-0.44 (-43.14%)
since 10/18/18
52-Week
0.46 +26.09%
on 12/28/18
2.55 -77.25%
on 04/10/18
-0.59 (-50.43%)
since 01/18/18

Most Recent Stories

More News
DURECT Corporation Provides Corporate Update

DURECT Corporation (Nasdaq: DRRX) has refined and focused its clinical development strategy for DUR-928, the lead product candidate in its Epigenetic Regulator Program, to prioritize indications with unmet...

DRRX : 0.58 (-3.33%)
DURECT Corporation Announces Investor Call to Provide Corporate Update

DURECT Corporation (Nasdaq: DRRX) invites interested parties to listen to a corporate update conference call that will be broadcast live over the internet on Monday, January 7, 2019 at 8:00 am Eastern...

DRRX : 0.58 (-3.33%)
Commercial Launch Plans Announced for PERSERIS(TM) (risperidone) Extended-Release Injectable Suspension for the Treatment of Schizophrenia in Adults

DURECT Corporation (Nasdaq: DRRX) today announced that Indivior PLC (LON: INDV) stated on December 18, 2018 that it is moving ahead with the launch of PERSERIS(TM) in the U.S. with a sales force consisting...

DRRX : 0.58 (-3.33%)
IZQVF : 1.6050 (+4.90%)
DURECT Corporation Announces Retirement of Dr. Felix Theeuwes as Chairman of the Board and Distinguished Scientist

DURECT Corporation (Nasdaq: DRRX) announced today that Felix Theeuwes will retire as Chairman of the Board and Distinguished Scientist effective December 31, 2018. Dr. Theeuwes has been scaling back his...

DRRX : 0.58 (-3.33%)
Analysis: Positioning to Benefit within News Corporation, DURECT, Ecolab, MiX Telematics, Ship Finance International, and BCE -- Research Highlights Growth, Revenue, and Consolidated Results

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of News Corporation (NASDAQ:NWS),...

DRRX : 0.58 (-3.33%)
BCE : 42.04 (+0.38%)
SFL : 11.85 (+2.24%)
NWS : 12.68 (+0.63%)
MIXT : 15.12 (-0.92%)
ECL : 154.50 (+1.30%)
DURECT Announces Amendment to Accelerate Ongoing Phase 2a Trial of DUR-928 in Alcoholic Hepatitis (AH) by Allowing Dosing of Severe AH Patients in Parallel to Moderate AH Patients

DURECT Corporation (Nasdaq: DRRX) today announced it has amended its ongoing Phase 2a clinical trial of intravenously administered DUR-928 in patients with alcoholic hepatitis (AH) to accelerate the initiation...

DRRX : 0.58 (-3.33%)
Durect: 3Q Earnings Snapshot

CUPERTINO, Calif. (AP) _ Durect Corp. (DRRX) on Wednesday reported a third-quarter loss of $2.7 million, after reporting a profit in the same period a year earlier.

DRRX : 0.58 (-3.33%)
DURECT Corporation Announces Third Quarter 2018 Financial Results and Provides Corporate Update

DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended September 30, 2018 and provided a corporate update.

DRRX : 0.58 (-3.33%)
DURECT Corporation Invites You to Join its Third Quarter 2018 Earnings Conference Call

In conjunction with DURECT Corporation's (Nasdaq: DRRX) third quarter 2018 financial results press release, you are invited to listen to a conference call that will be broadcast live over the internet...

DRRX : 0.58 (-3.33%)
DURECT Announces Abstracts on DUR-928 to be Presented at Upcoming Scientific Meetings

DURECT Corporation (Nasdaq: DRRX) announced today that two posters on DUR-928 will be presented at the ASN Kidney Week Meeting on Saturday, October 27 and one poster will be presented at the American College...

DRRX : 0.58 (-3.33%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Trade DRRX with:

Business Summary

Durect Corp. is pioneering the treatment of chronic diseases and conditions by developing and commercializing pharmaceutical systems to deliver the right drug to the right place in the right amount at the right time. Its pharmaceutical systems combine engineering innovations and delivery technology from...

See More

Key Turning Points

2nd Resistance Point 0.64
1st Resistance Point 0.61
Last Price 0.58
1st Support Level 0.56
2nd Support Level 0.54

See More

52-Week High 2.55
Fibonacci 61.8% 1.75
Fibonacci 50% 1.50
Fibonacci 38.2% 1.26
Last Price 0.58
52-Week Low 0.46

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar